AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Novavax, Inc.
Video analysis: NVAX
All videosNo video analysis for this stock yet. Request one from our team.
News: NVAX
Novavax (NVAX) Laps the Stock Market: Here's Why
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference
Novavax NASDAQ: NVAX outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healthcare Conference.
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Novavax to Participate in September Investor Conferences
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, New YorkFireside chat on Wednesday, September 9, 2026, at 9:45 a.m.
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
Novavax Inc. (NASDAQ:NVAX) shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.
